An order given by US District Judge William Young in a big-pharma antitrust case has appointed lead counsel to the case, but not without pointing out what he called “unseemly squabble” among the plaintiffs’ firms over who would win that lead. The suit concerns AstraZeneca which, along with three other generic drug makers, drug wholesalers have accused of colluding together to keep AstraZeneca’s heartburn drug Nexium off the sheves. Judge Young appointed the Hagens Berman Sobol Shapiro group to lead the case, but not without harshly commenting on the fight for the lead, in which Grant & Eisenhofer, Garwin Gerstein & Fisher and Berger & Montague also took part. In the words of Judge Young, the fight between the firms was more about who would be awarded the most attorneys’ fees rather than who was best-suited to lead the antitrust case.
Featured News
Trump’s Defamation Case Against New York Times Advances in Federal Court
Nov 19, 2026 by
CPI
Musk’s xAI Faces Skeptical US Judges Over California AI Disclosure Law
Nov 19, 2026 by
CPI
Italy Ends Vorwerk Antitrust Probe After Consumer Compensation Deal
Nov 19, 2026 by
CPI
Canada Wins Court Order to Advance Gap, Old Navy Advertising Probe
Nov 19, 2026 by
CPI
Russia Orders Major Retailers to Disclose Food Pricing Data in Antitrust Review
Nov 19, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Labor Market Collusion
Nov 19, 2026 by
CPI
From Price-Fixing to Wage-Fixing: Are Labor Markets the Next Frontier of Public and Private Competition Law Enforcement?
Nov 19, 2026 by
Giulia Rurali & Carsten Krüger
Damage Estimation and Labor Market Collusion
Nov 19, 2026 by
Louis D. Pape
Recent Developments of Labor Market Collusion in the EU: The Dialogue Between Delivery Hero and Tondela
Nov 19, 2026 by
Catarina Vieira Peres & Rita Ferreira Gomes
Enforcement in Labor Collusion and Monopsony: Trends and Challenges
Nov 19, 2026 by
Leyla Karakas & Anna Meyendorff